Mechanistic insights into sitagliptin’s action in rat inflammatory bowel disease: involvement of the NO-cGMP-KATP pathway
Background and purpose: Inflammatory bowel disease (IBD) involves several intestinal disorders that lead to prolonged inflammation of the gastrointestinal tract. Sitagliptin is an antidiabetic drug that works by increasing incretin hormones. This study examined the effect of sitagliptin, as well as the contribution of...